# Shield Therapeutics accelerating effectiveness of enlarged sales team

- Link: https://www.directorstalkinterviews.com/shield-therapeutics-accelerating-effectiveness-of-enlarged-sales-team/4121133386
- Published: 2023-11-20T09:43:53+00:00
- Author: Amilia Stone

**Shield Therapeutics plc **(LON:STX) is a commercial-stage pharma company delivering
specialty products that address patients’ unmet medical needs, with an initial focus
on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing
physician awareness of the differentiating characteristics of Accrufer® as an oral
ID drug, with the aim of ramping up prescription (Rx) growth and sales traction.
Positive Rx momentum in 2022 started to accelerate at the end of 1Q’23 and has continued
into 3Q’23, following expansion of the Shield-Viatris commercial team. In the event
that the US goals are achieved, there would be considerable upside potential to 
the valuation.

 * **Strategy:** In the US, Shield Therapeutics is commercialising Accrufer alongside
   its co-marketing partner, Viatris. Outside the US, Shield’s strategy is to out-
   license commercial rights to partners with appropriate expertise in target markets,
   which has been achieved so far in Europe, China, Republic of Korea and Canada.
 * **Accrufer Rx:** The interim results statement indicated that Accrufer Rx growth
   is accelerating following recruitment and training of the expanded field force,
   albeit slightly below our forecast. The indicative 80% growth rate in 3Q’23 is
   expected to be confirmed in a statement towards the end of November.
 * **Valuation:** Although Accrufer Rxs were modestly below our forecast, the market
   was more disappointed by the unexpected capital increase accompanying the loan
   refinancing package. However, if Shield gets anywhere close to its revised 2024
   and 2025 Rx numbers, the stock will appear cheap.
 * **Risks:** Commercial execution is key. The QoQ momentum in Rx growth has greatly
   reduced the risk. By 4Q’23, the 100-strong sales team, together with Viatris’s
   well-established network, should boost both Rxs and confidence. More challenging
   is the reduction in average discount for each Accrufer Rx.
 * **Investment summary: **During 2023, the market has continued to fret about whether
   the acceleration in Rx needed to hit full-year targets will be achieved. Early
   benefits to Accrufer Rxs from the enlarged and trained Shield Therapeutics-Viatris
   sales team were further evident in 1H’23, which augurs well for the future and
   the achievement of sales forecasts. The next update will be confirmation of 3Q’
   23 Rx data in November, followed by a full-year trading update in January 2024.

Share on:
